Clinical Inquiries

How effective and safe is fecal microbial transplant in preventing C difficile recurrence?

Author and Disclosure Information

EVIDENCE-BASED ANSWER:

Fecal microbial transplant (FMT) is reasonably safe and effective. In patients who have had multiple Clostridium difficile infections (CDIs), FMT results in a 65% to 80% cure rate with one treatment and 90% to 95% cure rate with repeated treatments compared with a 25% to 27% cure rate for antibiotics (strength of recommendation [SOR]: B, small open-label randomized controlled trials [RCTs]).

Fresh and frozen donor feces, administered by either nasogastric tube or colonoscope, produce equal results (SOR B, RCTs).

FMT has an overall adverse event rate of 30%, primarily involving abdominal discomfort, but also, rarely, severe infections (0.7%) and death (0.1%) (SOR: B, systematic review not limited to RCTs).


 

References

EVIDENCE SUMMARY

An open-label RCT enrolled 41 immunocompetent older adults who had relapsed CDI after at least one course of antibiotic therapy.1 Investigators randomized patients to 3 treatment groups:

  • vancomycin therapy, bowel lavage (with 4 L nasogastric polyethylene glycol solution), and nasogastric-infused fresh donor feces;
  • vancomycin with nasogastric bowel lavage without donor feces; or
  • vancomycin alone.

Researchers defined cure as the absence of diarrhea or 3 negative stool samples (if patients continued to have persistent diarrhea) at 10 weeks without relapse.

Thirteen of 16 patients (81%) in the donor feces infusion group were cured with the first infusion. Two of the 3 remaining patients were cured after a second donor transplant. FMT produced higher total cure rates than those of vancomycin (94% vs 27%; P<.001; number needed to treat [NNT]=2). Bowel lavage had no effect on outcome.

FMT cures more patients than vancomycin alone

An open-label RCT of 39 patients compared healthy-donor, fresh FMT given via colonoscopy with vancomycin alone for recurrent CDIs.2 Researchers recruited immunocompetent adults who had recurrent CDIs after at least one course of vancomycin or metronidazole.

Patients in the treatment group received a short course of vancomycin, followed by bowel cleansing and fecal transplant via colonoscopy. Clinicians repeated the fecal transplant every 3 days until resolution for patients with pseudomembranous colitis. Patients in the control group were treated with vancomycin for at least 3 weeks. Researchers defined cure as the absence of diarrhea or 2 negative stool samples (if patients continued to have diarrhea) at 10 weeks without relapse.

Thirteen of 20 patients in the FMT group (65%) achieved cure after the first fecal infusion. The 7 remaining patients received multiple infusions; 5 were cured. Overall, FMT cured more patients than vancomycin alone (90% vs 26%; odds ratio=25.2; 99.9% confidence interval [CI], 1.26-502; NNT=2).

Continue to: Fresh and frozen stool are equally effective

Pages

Evidence-based answers from the Family Physicians Inquiries Network

Recommended Reading

Breath test may detect esophagogastric cancer
MDedge Family Medicine
How to choose between highly effective HBV therapies
MDedge Family Medicine
VIDEO: Characteristic flora define intestinal microbiome in scleroderma
MDedge Family Medicine
Blood type A linked to more-severe diarrhea
MDedge Family Medicine
IBD upped Parkinson’s risk in large study
MDedge Family Medicine
FDA approves Doptelet for liver disease patients undergoing procedures
MDedge Family Medicine
Recent studies of microbiota offer insights into digestive disease management
MDedge Family Medicine
Experimental drug may help those living with celiac disease
MDedge Family Medicine
MDedge Daily News: Keeping patients summer safe
MDedge Family Medicine
FDA expands Xeljanz approval to certain adults with ulcerative colitis
MDedge Family Medicine